DDInter826 DDInter535
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255647,L44612]
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Glipizide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glipizide {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Glipizide {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Diazoxide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) binds {v} (Gene) CA1
CA1 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glipizide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) interacts with {v} (Gene) ABCC8
ABCC8 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glipizide {u} (Compound) binds {v} (Gene) ABCC8
ABCC8 {u} (Gene) interacts with {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glipizide {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is regulated by {v} (Gene) CA2
CA2 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glipizide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is regulated by {v} (Gene) KRT19
KRT19 {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Glipizide {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Glipizide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Diazoxide (Compound)
Glipizide (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Diazoxide (Compound)
Glipizide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Diazoxide (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) binds CA1 (Gene) and CA1 (Gene) is bound by Diazoxide (Compound)
Glipizide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) interacts with ABCC8 (Gene) and ABCC8 (Gene) is bound by Diazoxide (Compound)
Glipizide (Compound) binds ABCC8 (Gene) and ABCC8 (Gene) interacts with KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Diazoxide (Compound)
Glipizide (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is regulated by CA2 (Gene) and CA2 (Gene) is bound by Diazoxide (Compound)
Glipizide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is regulated by KRT19 (Gene) and KRT19 (Gene) is upregulated by Diazoxide (Compound)
Glipizide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)